Convergent Therapeutics will present Phase 2 CONV01-alpha data at ASCO 2026. Find out what this could mean for post-Lu-PSMA prostate cancer care.
Aulos Bioscience will present new imneskibart melanoma data at ASCO 2026. Read what it could mean for IL-2 therapy and immuno-oncology.
Pfizer’s ASCO 2026 oncology data span lorlatinib, talazoparib, tucatinib and new pipeline assets. Read what the updates could change next.
Uqora has entered Target stores and Target.com. Find out what this expansion means for urinary health retail and women’s wellness growth.
Genentech’s Enspryng cut MOGAD relapse risk by 68% in Phase III. Read what the data could mean for regulators, clinicians, and the rare disease market.
Tubulis presents updated TUB-040 Phase I/IIa data at ASCO 2026. Here is what the NAPISTAR 1-01 readout means for NaPi2b and ovarian cancer treatment.
FDA cleared blood-based collection for SOLVD Health’s AvertD. Find out why this could expand genetic opioid risk testing in surgical care.
Calluna Pharma finished Phase 2 AURORA enrollment early for CAL101 in IPF. Read what this means for fibrosis competition and Q1 2027 data.
Read how Johnson & Johnson’s ETHICON 4000 CE Mark approval could reshape surgical stapling, hospital economics, and future robotic integration.
4Moving Biotech’s 4P004 won FDA Fast Track in knee osteoarthritis. Read what this means for DMOAD development, trial risk, and regulatory strategy.